eBook (Meeting Coverage)

ECTRIMS NMOSD eBook

Dec 7, 2022

ECTRIMS NMOSD 2022a.indd

SOHO 2022 eBook

Dec 6, 2022

SOHO 2022 Conference Report.indd

ASCO a Focus on NMSC eBook

Aug 19, 2022

ASCO NMSC Annual Meetingv1.indd

ASCO A Focus On Leukemia eBook

Aug 18, 2022

ASCO Leukemia 2022.indd

ASCO: A Focus on Lung Cancer

Aug 15, 2022

ASCO Lung Cancer Annual 2022.indd

CMSC: A Focus On MS eBook

Aug 15, 2022

CMSC ON MS Conference Report.indd

AAN 2022 eBOOK: A Focus on Multiple Sclerosis

Jun 7, 2022

AAN 2022 MS Neurov1.indd

ACTRIMS eBook

May 24, 2022

Focus on MS MAY 2022v2.indd

SGO eBook

May 5, 2022

SGO Gynecologic Cancer 2022

ASCO GU eBook

Apr 4, 2022

ASCO Genitourinary Cancer Renal 2022.indd

ASH 2021: A Focus on Leukemia & Lymphoma

Jan 12, 2022

Focus on Lymphoma Leukemia

Patients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs

Jan 10, 2022

According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...

Venetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL

Jan 10, 2022

The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...

Delayed Start of Therapy Feasible in Some Patients With MCL

Jan 10, 2022

Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...

Addition of Ibrutinib to Chemoimmunotherapy in CLL

Jan 8, 2022

The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...